[
  {
    "title": "多瑞医药：六成营收用来推广，靠未形成销售的布洛芬股价起飞？",
    "href": "http://stock.jrj.com.cn/2022/12/21115137227834.shtml",
    "datetime": "2022-12-21 11:51:00",
    "code": "301075"
  },
  {
    "title": "【龙虎榜】多瑞医药12月20日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/12/20180237226122.shtml",
    "datetime": "2022-12-20 18:02:07",
    "code": "301075"
  },
  {
    "title": "【龙虎榜】多瑞医药12月16日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/12/16180537218769.shtml",
    "datetime": "2022-12-16 18:05:15",
    "code": "301075"
  },
  {
    "title": "多瑞医药：布洛芬混悬液正按计划组织生产 尚未形成销售",
    "href": "http://stock.jrj.com.cn/2022/12/14192637212861.shtml",
    "datetime": "2022-12-14 19:26:51",
    "code": "301075"
  },
  {
    "title": "【龙虎榜】多瑞医药12月14日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/12/14180437212531.shtml",
    "datetime": "2022-12-14 18:04:50",
    "code": "301075"
  },
  {
    "title": "【龙虎榜】多瑞医药12月12日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/12/12180137206453.shtml",
    "datetime": "2022-12-12 18:01:11",
    "code": "301075"
  },
  {
    "title": "多瑞医药数亿推广费畸高连续四年占营收超60% 邓勇力推跨界难见效前三季扣非仅948万",
    "href": "http://stock.jrj.com.cn/2022/12/05110737187965.shtml",
    "datetime": "2022-12-05 11:07:01",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：左氧氟沙星氯化钠注射液药品注册申请获受理",
    "href": "http://stock.jrj.com.cn/2022/11/18171337150383.shtml",
    "datetime": "2022-11-18 17:13:30",
    "code": "301075"
  },
  {
    "title": "多瑞医药：收到左氧氟沙星氯化钠注射液药品注册受理通知书",
    "href": "http://stock.jrj.com.cn/2022/11/18165937150284.shtml",
    "datetime": "2022-11-18 16:59:32",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：碳酸氢钠林格注射液获批上市",
    "href": "http://stock.jrj.com.cn/2022/11/17173737147165.shtml",
    "datetime": "2022-11-17 17:37:54",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：终止受让湖北天济所持亳州天济40%股权",
    "href": "http://stock.jrj.com.cn/2022/11/16171937143967.shtml",
    "datetime": "2022-11-16 17:19:00",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拟6000万元增资湖北天济 占投后5.66%",
    "href": "http://stock.jrj.com.cn/2022/11/16171537143975.shtml",
    "datetime": "2022-11-16 17:15:49",
    "code": "301075"
  },
  {
    "title": "多瑞医药注销控股子公司仁康医药：2021年营收为0元净利润194万元",
    "href": "http://stock.jrj.com.cn/2022/10/14105037055063.shtml",
    "datetime": "2022-10-14 10:50:07",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：注销控股子公司仁康医药",
    "href": "http://stock.jrj.com.cn/2022/10/13171437053183.shtml",
    "datetime": "2022-10-13 17:14:23",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)拟400万元增资朗皓医疗 投后占比25%",
    "href": "http://stock.jrj.com.cn/2022/10/10171937044227.shtml",
    "datetime": "2022-10-10 17:19:14",
    "code": "301075"
  },
  {
    "title": "多瑞医药：与中创医疗签订销售代理协议",
    "href": "http://stock.jrj.com.cn/2022/09/09160936986250.shtml",
    "datetime": "2022-09-09 16:09:54",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拟以400万元收购海瑞迪余下30%股权",
    "href": "http://stock.jrj.com.cn/2022/09/01204436964277.shtml",
    "datetime": "2022-09-01 20:44:45",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：与海融医药签署战略合作协议",
    "href": "http://stock.jrj.com.cn/2022/09/01204336964280.shtml",
    "datetime": "2022-09-01 20:43:15",
    "code": "301075"
  },
  {
    "title": "多瑞医药：与海融医药签署战略合作协议",
    "href": "http://stock.jrj.com.cn/2022/09/01202736964170.shtml",
    "datetime": "2022-09-01 20:27:53",
    "code": "301075"
  },
  {
    "title": "多瑞医药上半年盈利1383万元：超前投入研发创新 新增长极快速崛起",
    "href": "http://stock.jrj.com.cn/2022/08/26145236940456.shtml",
    "datetime": "2022-08-26 14:52:50",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)上半年净利1383.24万元，同比下降62.69%",
    "href": "http://stock.jrj.com.cn/2022/08/26101736939469.shtml",
    "datetime": "2022-08-26 10:17:30",
    "code": "301075"
  },
  {
    "title": "多瑞医药：公司拟受让湖北天济持有的亳州天济40%股权",
    "href": "http://stock.jrj.com.cn/2022/08/10103336885716.shtml",
    "datetime": "2022-08-10 10:33:26",
    "code": "301075"
  },
  {
    "title": "多瑞医药：签署投资意向协议 拟受让亳州天济40%股权",
    "href": "http://stock.jrj.com.cn/2022/08/10090636885492.shtml",
    "datetime": "2022-08-10 09:06:23",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拟受让湖北天济所持有的亳州天济40%股权",
    "href": "http://stock.jrj.com.cn/2022/08/09203936884301.shtml",
    "datetime": "2022-08-09 20:39:12",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拿下科伦药业心可舒颗粒中国独代权",
    "href": "http://stock.jrj.com.cn/2022/07/25160536840060.shtml",
    "datetime": "2022-07-25 16:05:54",
    "code": "301075"
  },
  {
    "title": "多瑞医药：与湖北济安堂签署独家代理协议 代理产品为滋补水鸭合剂",
    "href": "http://stock.jrj.com.cn/2022/07/07150136790928.shtml",
    "datetime": "2022-07-07 15:01:28",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：独家代理湖北济安堂滋补水鸭合剂",
    "href": "http://stock.jrj.com.cn/2022/07/06185636787987.shtml",
    "datetime": "2022-07-06 18:56:33",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：签订终止来曲唑片内地总代理协议",
    "href": "http://stock.jrj.com.cn/2022/07/01174936775834.shtml",
    "datetime": "2022-07-01 17:49:42",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：收到氨甲环酸注射液的药品注册受理通知书",
    "href": "http://stock.jrj.com.cn/2022/06/28223736766088.shtml",
    "datetime": "2022-06-28 22:37:40",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：注销全资子公司湖北本阳",
    "href": "http://stock.jrj.com.cn/2022/05/16200936652612.shtml",
    "datetime": "2022-05-16 20:09:31",
    "code": "301075"
  },
  {
    "title": "多瑞医药：与朗皓医疗签订销售代理协议 有利于丰富公司品种结构和战略布局",
    "href": "http://stock.jrj.com.cn/2022/05/11185336635931.shtml",
    "datetime": "2022-05-11 18:53:38",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：与朗皓医疗签署独家代理协议",
    "href": "http://stock.jrj.com.cn/2022/05/11164336633989.shtml",
    "datetime": "2022-05-11 16:43:15",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拟出资560万元成立控股子公司海瑞迪医药",
    "href": "http://stock.jrj.com.cn/2022/04/22164936429271.shtml",
    "datetime": "2022-04-22 16:49:24",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：2021年年度权益分派10派6.25元 股权登记日4月26日",
    "href": "http://stock.jrj.com.cn/2022/04/19211836402297.shtml",
    "datetime": "2022-04-19 21:18:06",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：湖北多瑞成为注射用尿激酶(10万单位)上市许可持有人",
    "href": "http://stock.jrj.com.cn/2022/04/06181936263661.shtml",
    "datetime": "2022-04-06 18:19:51",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：成立武汉全资子公司",
    "href": "http://stock.jrj.com.cn/2022/03/28194935924287.shtml",
    "datetime": "2022-03-28 19:49:30",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：2021年度净利润降25.53%至6850.79万元 拟10派6.25元",
    "href": "http://stock.jrj.com.cn/2022/03/24204334938739.shtml",
    "datetime": "2022-03-24 20:43:14",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：子公司1560万元购得“益肺济生颗粒”新药临床批件",
    "href": "http://stock.jrj.com.cn/2022/02/22171134434949.shtml",
    "datetime": "2022-02-22 17:11:28",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)拟斥1280万元成立控股子公司瑞蒂莲医药",
    "href": "http://stock.jrj.com.cn/2022/02/07124734299146.shtml",
    "datetime": "2022-02-07 12:47:09",
    "code": "301075"
  },
  {
    "title": "多瑞医药：为进一步优化股权投资结构 拟收购控股子公司嘉诺康剩余20%股权",
    "href": "http://stock.jrj.com.cn/2022/01/21141834182381.shtml",
    "datetime": "2022-01-21 14:18:18",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拟300万元收购嘉诺康剩余20%股权",
    "href": "http://stock.jrj.com.cn/2022/01/21121734182028.shtml",
    "datetime": "2022-01-21 12:17:44",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：成立全资子公司潜江多瑞药业有限公司",
    "href": "http://stock.jrj.com.cn/2022/01/20173034179022.shtml",
    "datetime": "2022-01-20 17:30:00",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)拿下济南康桥盐酸罗哌卡因氯化钠注射液全国独代",
    "href": "http://stock.jrj.com.cn/2022/01/18155434169713.shtml",
    "datetime": "2022-01-18 15:54:09",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：成立全资子公司武汉多瑞实业",
    "href": "http://stock.jrj.com.cn/2022/01/07161734133652.shtml",
    "datetime": "2022-01-07 16:17:19",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)拿下培力药品来曲唑片大陆独家代理",
    "href": "http://stock.jrj.com.cn/2022/01/05184434124851.shtml",
    "datetime": "2022-01-05 18:44:05",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：盐酸文拉法辛缓释胶囊上市申请获受理",
    "href": "http://stock.jrj.com.cn/2021/12/30195034088042.shtml",
    "datetime": "2021-12-30 19:50:31",
    "code": "301075"
  },
  {
    "title": "多瑞医药：西藏嘉康所持210万股质押 占公司总股本比例2.63%",
    "href": "http://stock.jrj.com.cn/2021/12/27135734070010.shtml",
    "datetime": "2021-12-27 13:57:25",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)及子公司拟向银行申请4.2亿元综合授信",
    "href": "http://stock.jrj.com.cn/2021/12/27122334069564.shtml",
    "datetime": "2021-12-27 12:23:33",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拟将2630万元超募资金用于永久补流",
    "href": "http://stock.jrj.com.cn/2021/12/27121934069561.shtml",
    "datetime": "2021-12-27 12:19:42",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拟使用额度不超1亿元闲置自有资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/12/10203533995999.shtml",
    "datetime": "2021-12-10 20:35:34",
    "code": "301075"
  },
  {
    "title": "【龙虎榜】多瑞医药11月16日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/11/16180133861086.shtml",
    "datetime": "2021-11-16 18:01:53",
    "code": "301075"
  },
  {
    "title": "多瑞医药业绩首秀证明盈利能力 务实理性成就血浆代用品“隐形冠军”",
    "href": "http://stock.jrj.com.cn/2021/10/25103333746095.shtml",
    "datetime": "2021-10-25 10:33:53",
    "code": "301075"
  },
  {
    "title": "三季度盈利增长超预期，核心产品市占率超90%的多瑞医药彰显价值稀有性",
    "href": "http://stock.jrj.com.cn/2021/10/21201533729103.shtml",
    "datetime": "2021-10-21 20:15:51",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拟使用募集资金向全资子公司增资实施募投项目",
    "href": "http://stock.jrj.com.cn/2021/10/20201233723348.shtml",
    "datetime": "2021-10-20 20:12:33",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：拟使用不超4.5亿元闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/10/20201033723337.shtml",
    "datetime": "2021-10-20 20:10:27",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)第三季度净利润1223.03万元 同比下降15.12%",
    "href": "http://stock.jrj.com.cn/2021/10/20200833723332.shtml",
    "datetime": "2021-10-20 20:08:50",
    "code": "301075"
  },
  {
    "title": "【龙虎榜】多瑞医药9月29日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/09/29180233537407.shtml",
    "datetime": "2021-09-29 18:02:01",
    "code": "301075"
  },
  {
    "title": "多瑞医药上市首日涨65% IPO募5.5亿中信证券赚0.4亿",
    "href": "http://stock.jrj.com.cn/2021/09/29160433536617.shtml",
    "datetime": "2021-09-29 16:04:00",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)将于9月29日在创业板上市",
    "href": "http://stock.jrj.com.cn/2021/09/27212033525597.shtml",
    "datetime": "2021-09-27 21:20:28",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)披露网上发行结果：遭弃购29473股 由主承销商包销",
    "href": "http://stock.jrj.com.cn/2021/09/22204233500229.shtml",
    "datetime": "2021-09-22 20:42:40",
    "code": "301075"
  },
  {
    "title": "【兑奖啦】多瑞医药网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2021/09/16195633446632.shtml",
    "datetime": "2021-09-16 19:56:49",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)IPO网上定价发行摇号中签结果出炉：中签号共4万个",
    "href": "http://stock.jrj.com.cn/2021/09/16194633446541.shtml",
    "datetime": "2021-09-16 19:46:52",
    "code": "301075"
  },
  {
    "title": "多瑞医药(301075.SZ)：网上定价发行的中签率为0.0116201892%",
    "href": "http://stock.jrj.com.cn/2021/09/15201933441094.shtml",
    "datetime": "2021-09-15 20:19:38",
    "code": "301075"
  },
  {
    "title": "今日申购：多瑞医药",
    "href": "http://stock.jrj.com.cn/2021/09/15085733437729.shtml",
    "datetime": "2021-09-15 08:57:00",
    "code": "301075"
  },
  {
    "title": "创业板第31次审议会议结出炉：通灵电器、多瑞医药、泽宇智能首发过会",
    "href": "http://stock.jrj.com.cn/2021/06/12050432914813.shtml",
    "datetime": "2021-06-12 05:04:18",
    "code": "301075"
  }
]